The periaqueductal grey is a critical site in the neuronal network for audiogenic seizures: modulation by GABA A, NMDA and opioid receptors
The nuclei comprising the neuronal network for audiogenic seizures (AGS) are located primarily in the brainstem. Previous studies suggested a role for the periaqueductal grey (PAG) in the AGS network. The present study evaluated this possibility in genetically-epilepsy prone rats (GEPR-9s) by examin...
Gespeichert in:
| Veröffentlicht in: | Epilepsy research 1999-05, Vol.35 (1), p.39-46 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 46 |
|---|---|
| container_issue | 1 |
| container_start_page | 39 |
| container_title | Epilepsy research |
| container_volume | 35 |
| creator | N’Gouemo, Prosper Faingold, Carl L |
| description | The nuclei comprising the neuronal network for audiogenic seizures (AGS) are located primarily in the brainstem. Previous studies suggested a role for the periaqueductal grey (PAG) in the AGS network. The present study evaluated this possibility in genetically-epilepsy prone rats (GEPR-9s) by examining the effects of bilateral focal microinjection of a competitive NMDA receptor antagonist (
dl-2-amino-7-phosphonoheptanoic acid (AP7), 1 and 5 nmol/side), a GABA
A agonist (gaboxedol (THIP), 10 and 15 nmol) or an opioid peptide receptor antagonist (naloxone, 5 nmol) into PAG, based on the proposed role of these receptors in PAG neurotransmission. Blockade of NMDA receptors by AP7 (both doses) or activation of GABA
A receptors with THIP (15 nmol/side) in the PAG suppressed AGS susceptibility. Naloxone displayed a seizure-suppressant effect that was delayed and incomplete. The seizure suppressant effect of AP7 or naloxone, unlike THIP, was observed at doses that did not produce motor quiescence. These data suggest that the PAG is a requisite nucleus in the neuronal network for AGS in GEPR-9s and that GABA
A, opioid peptide and NMDA receptors in the PAG modulate AGS propagation. |
| doi_str_mv | 10.1016/S0920-1211(98)00128-4 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_69734927</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0920121198001284</els_id><sourcerecordid>69734927</sourcerecordid><originalsourceid>FETCH-LOGICAL-e292t-c9f05c7ffd7b22257aec684f14b96f13b06b149777a9f860d8fea1431403b07c3</originalsourceid><addsrcrecordid>eNo9kc1u1TAQRi1ERS-FRwDNCoFEwHbcOO4GhdIWpAILytpy7HEx5MbBdoour8BL4_7AaqSZo9F8cwh5wugrRln3-gtVnDaMM_Zc9S8oZbxvxD2yYb3kTdcLcZ9s_iP75GHO3ymlkgrxgOwzylsuVbshfy6-ISyYgvm5olttMRNcJtxByGDAplCCra0cCkKYoVR6xjXFuTZnLL9i-gE-JjCrC_ES52AhY_i9JsxHsI1unUwJcYZxB2fD2wGGl_Dp47sBzOwgLiEGBwktLiWm_IjseTNlfHxXD8jX05OL4_fN-eezD8fDeYNc8dJY5emhld47OXLOD6VBWwN7JkbVedaOtBuZUFJKo3zfUdd7NEy0TNA6k7Y9IM9u9y4p1tS56G3IFqfJzBjXrDslW6G4rODTO3Adt-j0ksLWpJ3-974KvLkFsJ57FTDpbAPOFl2oqYp2MVRYXwvTN8L0tQ2ten0jTIv2L-6Bh5w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>69734927</pqid></control><display><type>article</type><title>The periaqueductal grey is a critical site in the neuronal network for audiogenic seizures: modulation by GABA A, NMDA and opioid receptors</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>N’Gouemo, Prosper ; Faingold, Carl L</creator><creatorcontrib>N’Gouemo, Prosper ; Faingold, Carl L</creatorcontrib><description>The nuclei comprising the neuronal network for audiogenic seizures (AGS) are located primarily in the brainstem. Previous studies suggested a role for the periaqueductal grey (PAG) in the AGS network. The present study evaluated this possibility in genetically-epilepsy prone rats (GEPR-9s) by examining the effects of bilateral focal microinjection of a competitive NMDA receptor antagonist (
dl-2-amino-7-phosphonoheptanoic acid (AP7), 1 and 5 nmol/side), a GABA
A agonist (gaboxedol (THIP), 10 and 15 nmol) or an opioid peptide receptor antagonist (naloxone, 5 nmol) into PAG, based on the proposed role of these receptors in PAG neurotransmission. Blockade of NMDA receptors by AP7 (both doses) or activation of GABA
A receptors with THIP (15 nmol/side) in the PAG suppressed AGS susceptibility. Naloxone displayed a seizure-suppressant effect that was delayed and incomplete. The seizure suppressant effect of AP7 or naloxone, unlike THIP, was observed at doses that did not produce motor quiescence. These data suggest that the PAG is a requisite nucleus in the neuronal network for AGS in GEPR-9s and that GABA
A, opioid peptide and NMDA receptors in the PAG modulate AGS propagation.</description><identifier>ISSN: 0920-1211</identifier><identifier>EISSN: 1872-6844</identifier><identifier>DOI: 10.1016/S0920-1211(98)00128-4</identifier><identifier>PMID: 10232793</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>2-Amino-5-phosphonovalerate - analogs & derivatives ; 2-Amino-5-phosphonovalerate - pharmacology ; Animals ; Audiogenic seizures ; Excitatory Amino Acid Agonists - pharmacology ; Excitatory Amino Acid Antagonists - pharmacology ; GABA ; GABA-A Receptor Agonists ; Isoxazoles - pharmacology ; Male ; Microinjections ; Naloxone ; Naloxone - pharmacology ; Narcotic Antagonists - pharmacology ; Nerve Net - pathology ; Nerve Net - physiopathology ; Neuronal network ; NMDA ; Periaqueductal Gray - pathology ; Periaqueductal Gray - physiopathology ; Periaqueductal grey ; Rats ; Receptors, GABA-A - drug effects ; Receptors, N-Methyl-D-Aspartate - antagonists & inhibitors ; Receptors, N-Methyl-D-Aspartate - drug effects ; Receptors, Opioid - drug effects ; Seizures - genetics ; Seizures - physiopathology</subject><ispartof>Epilepsy research, 1999-05, Vol.35 (1), p.39-46</ispartof><rights>1999 Elsevier Science B.V.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/S0920-1211(98)00128-4$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10232793$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>N’Gouemo, Prosper</creatorcontrib><creatorcontrib>Faingold, Carl L</creatorcontrib><title>The periaqueductal grey is a critical site in the neuronal network for audiogenic seizures: modulation by GABA A, NMDA and opioid receptors</title><title>Epilepsy research</title><addtitle>Epilepsy Res</addtitle><description>The nuclei comprising the neuronal network for audiogenic seizures (AGS) are located primarily in the brainstem. Previous studies suggested a role for the periaqueductal grey (PAG) in the AGS network. The present study evaluated this possibility in genetically-epilepsy prone rats (GEPR-9s) by examining the effects of bilateral focal microinjection of a competitive NMDA receptor antagonist (
dl-2-amino-7-phosphonoheptanoic acid (AP7), 1 and 5 nmol/side), a GABA
A agonist (gaboxedol (THIP), 10 and 15 nmol) or an opioid peptide receptor antagonist (naloxone, 5 nmol) into PAG, based on the proposed role of these receptors in PAG neurotransmission. Blockade of NMDA receptors by AP7 (both doses) or activation of GABA
A receptors with THIP (15 nmol/side) in the PAG suppressed AGS susceptibility. Naloxone displayed a seizure-suppressant effect that was delayed and incomplete. The seizure suppressant effect of AP7 or naloxone, unlike THIP, was observed at doses that did not produce motor quiescence. These data suggest that the PAG is a requisite nucleus in the neuronal network for AGS in GEPR-9s and that GABA
A, opioid peptide and NMDA receptors in the PAG modulate AGS propagation.</description><subject>2-Amino-5-phosphonovalerate - analogs & derivatives</subject><subject>2-Amino-5-phosphonovalerate - pharmacology</subject><subject>Animals</subject><subject>Audiogenic seizures</subject><subject>Excitatory Amino Acid Agonists - pharmacology</subject><subject>Excitatory Amino Acid Antagonists - pharmacology</subject><subject>GABA</subject><subject>GABA-A Receptor Agonists</subject><subject>Isoxazoles - pharmacology</subject><subject>Male</subject><subject>Microinjections</subject><subject>Naloxone</subject><subject>Naloxone - pharmacology</subject><subject>Narcotic Antagonists - pharmacology</subject><subject>Nerve Net - pathology</subject><subject>Nerve Net - physiopathology</subject><subject>Neuronal network</subject><subject>NMDA</subject><subject>Periaqueductal Gray - pathology</subject><subject>Periaqueductal Gray - physiopathology</subject><subject>Periaqueductal grey</subject><subject>Rats</subject><subject>Receptors, GABA-A - drug effects</subject><subject>Receptors, N-Methyl-D-Aspartate - antagonists & inhibitors</subject><subject>Receptors, N-Methyl-D-Aspartate - drug effects</subject><subject>Receptors, Opioid - drug effects</subject><subject>Seizures - genetics</subject><subject>Seizures - physiopathology</subject><issn>0920-1211</issn><issn>1872-6844</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1999</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kc1u1TAQRi1ERS-FRwDNCoFEwHbcOO4GhdIWpAILytpy7HEx5MbBdoour8BL4_7AaqSZo9F8cwh5wugrRln3-gtVnDaMM_Zc9S8oZbxvxD2yYb3kTdcLcZ9s_iP75GHO3ymlkgrxgOwzylsuVbshfy6-ISyYgvm5olttMRNcJtxByGDAplCCra0cCkKYoVR6xjXFuTZnLL9i-gE-JjCrC_ES52AhY_i9JsxHsI1unUwJcYZxB2fD2wGGl_Dp47sBzOwgLiEGBwktLiWm_IjseTNlfHxXD8jX05OL4_fN-eezD8fDeYNc8dJY5emhld47OXLOD6VBWwN7JkbVedaOtBuZUFJKo3zfUdd7NEy0TNA6k7Y9IM9u9y4p1tS56G3IFqfJzBjXrDslW6G4rODTO3Adt-j0ksLWpJ3-974KvLkFsJ57FTDpbAPOFl2oqYp2MVRYXwvTN8L0tQ2ten0jTIv2L-6Bh5w</recordid><startdate>19990501</startdate><enddate>19990501</enddate><creator>N’Gouemo, Prosper</creator><creator>Faingold, Carl L</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>19990501</creationdate><title>The periaqueductal grey is a critical site in the neuronal network for audiogenic seizures: modulation by GABA A, NMDA and opioid receptors</title><author>N’Gouemo, Prosper ; Faingold, Carl L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-e292t-c9f05c7ffd7b22257aec684f14b96f13b06b149777a9f860d8fea1431403b07c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1999</creationdate><topic>2-Amino-5-phosphonovalerate - analogs & derivatives</topic><topic>2-Amino-5-phosphonovalerate - pharmacology</topic><topic>Animals</topic><topic>Audiogenic seizures</topic><topic>Excitatory Amino Acid Agonists - pharmacology</topic><topic>Excitatory Amino Acid Antagonists - pharmacology</topic><topic>GABA</topic><topic>GABA-A Receptor Agonists</topic><topic>Isoxazoles - pharmacology</topic><topic>Male</topic><topic>Microinjections</topic><topic>Naloxone</topic><topic>Naloxone - pharmacology</topic><topic>Narcotic Antagonists - pharmacology</topic><topic>Nerve Net - pathology</topic><topic>Nerve Net - physiopathology</topic><topic>Neuronal network</topic><topic>NMDA</topic><topic>Periaqueductal Gray - pathology</topic><topic>Periaqueductal Gray - physiopathology</topic><topic>Periaqueductal grey</topic><topic>Rats</topic><topic>Receptors, GABA-A - drug effects</topic><topic>Receptors, N-Methyl-D-Aspartate - antagonists & inhibitors</topic><topic>Receptors, N-Methyl-D-Aspartate - drug effects</topic><topic>Receptors, Opioid - drug effects</topic><topic>Seizures - genetics</topic><topic>Seizures - physiopathology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>N’Gouemo, Prosper</creatorcontrib><creatorcontrib>Faingold, Carl L</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Epilepsy research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>N’Gouemo, Prosper</au><au>Faingold, Carl L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The periaqueductal grey is a critical site in the neuronal network for audiogenic seizures: modulation by GABA A, NMDA and opioid receptors</atitle><jtitle>Epilepsy research</jtitle><addtitle>Epilepsy Res</addtitle><date>1999-05-01</date><risdate>1999</risdate><volume>35</volume><issue>1</issue><spage>39</spage><epage>46</epage><pages>39-46</pages><issn>0920-1211</issn><eissn>1872-6844</eissn><abstract>The nuclei comprising the neuronal network for audiogenic seizures (AGS) are located primarily in the brainstem. Previous studies suggested a role for the periaqueductal grey (PAG) in the AGS network. The present study evaluated this possibility in genetically-epilepsy prone rats (GEPR-9s) by examining the effects of bilateral focal microinjection of a competitive NMDA receptor antagonist (
dl-2-amino-7-phosphonoheptanoic acid (AP7), 1 and 5 nmol/side), a GABA
A agonist (gaboxedol (THIP), 10 and 15 nmol) or an opioid peptide receptor antagonist (naloxone, 5 nmol) into PAG, based on the proposed role of these receptors in PAG neurotransmission. Blockade of NMDA receptors by AP7 (both doses) or activation of GABA
A receptors with THIP (15 nmol/side) in the PAG suppressed AGS susceptibility. Naloxone displayed a seizure-suppressant effect that was delayed and incomplete. The seizure suppressant effect of AP7 or naloxone, unlike THIP, was observed at doses that did not produce motor quiescence. These data suggest that the PAG is a requisite nucleus in the neuronal network for AGS in GEPR-9s and that GABA
A, opioid peptide and NMDA receptors in the PAG modulate AGS propagation.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>10232793</pmid><doi>10.1016/S0920-1211(98)00128-4</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0920-1211 |
| ispartof | Epilepsy research, 1999-05, Vol.35 (1), p.39-46 |
| issn | 0920-1211 1872-6844 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_69734927 |
| source | MEDLINE; ScienceDirect Journals (5 years ago - present) |
| subjects | 2-Amino-5-phosphonovalerate - analogs & derivatives 2-Amino-5-phosphonovalerate - pharmacology Animals Audiogenic seizures Excitatory Amino Acid Agonists - pharmacology Excitatory Amino Acid Antagonists - pharmacology GABA GABA-A Receptor Agonists Isoxazoles - pharmacology Male Microinjections Naloxone Naloxone - pharmacology Narcotic Antagonists - pharmacology Nerve Net - pathology Nerve Net - physiopathology Neuronal network NMDA Periaqueductal Gray - pathology Periaqueductal Gray - physiopathology Periaqueductal grey Rats Receptors, GABA-A - drug effects Receptors, N-Methyl-D-Aspartate - antagonists & inhibitors Receptors, N-Methyl-D-Aspartate - drug effects Receptors, Opioid - drug effects Seizures - genetics Seizures - physiopathology |
| title | The periaqueductal grey is a critical site in the neuronal network for audiogenic seizures: modulation by GABA A, NMDA and opioid receptors |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T16%3A13%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20periaqueductal%20grey%20is%20a%20critical%20site%20in%20the%20neuronal%20network%20for%20audiogenic%20seizures:%20modulation%20by%20GABA%20A,%20NMDA%20and%20opioid%20receptors&rft.jtitle=Epilepsy%20research&rft.au=N%E2%80%99Gouemo,%20Prosper&rft.date=1999-05-01&rft.volume=35&rft.issue=1&rft.spage=39&rft.epage=46&rft.pages=39-46&rft.issn=0920-1211&rft.eissn=1872-6844&rft_id=info:doi/10.1016/S0920-1211(98)00128-4&rft_dat=%3Cproquest_pubme%3E69734927%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=69734927&rft_id=info:pmid/10232793&rft_els_id=S0920121198001284&rfr_iscdi=true |